المؤلفون: Maria Paola Belfiore, Valerio Nardone, Ida D’Onofrio, Antonio Alessandro Helliot Salvia, Emma D’Ippolito, Luigi Gallo, Valentina Caliendo, Gianluca Gatta, Morena Fasano, Roberta Grassi, Antonio Angrisani, Cesare Guida, Alfonso Reginelli, Salvatore Cappabianca

المصدر: Exploration of Targeted Anti-tumor Therapy, Vol 3, Iss 6, Pp 734-745 (2022)

مصطلحات موضوعية: diffusion-weighted imaging, magnetic resonance imaging, head and neck cancer, head and neck squamous cell cancer, lymph node, Internal medicine, RC31-1245

الوصف: Aim: Head and neck squamous cell cancer (HNSCC) is the ninth most common tumor worldwide. Neck lymph node (LN) status is the major indicator of prognosis in all head and neck cancers, and the early detection of LN involvement is crucial in terms of therapy and prognosis. Diffusion-weighted imaging (DWI) is a non- invasive imaging technique used in magnetic resonance imaging (MRI) to characterize tissues based on the displacement motion of water molecules. This review aims to provide an overview of the current literature concerning quantitative diffusion imaging for LN staging in patients with HNSCC. Methods: This systematic review performed a literature search on the PubMed database (https://pubmed.ncbi.nlm.nih.govTest/) for all relevant, peer-reviewed literature on the subject following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) criteria, using the keywords: DWI, MRI, head and neck, staging, lymph node. Results: After excluding reviews, meta-analyses, case reports, and bibliometric studies, 18 relevant papers out of the 567 retrieved were selected for analysis. Conclusions: DWI improves the diagnosis, treatment planning, treatment response evaluation, and overall management of patients affected by HNSCC. More robust data to clarify the role of apparent diffusion coefficient (ADC) and DWI parameters are needed to develop models for prognosis and prediction in HNSCC cancer using MRI.

وصف الملف: electronic resource

العلاقة: https://www.explorationpub.com/Journals/etat/Article/1002110Test; https://doaj.org/toc/2692-3114Test

الوصول الحر: https://doaj.org/article/f495603c7d2f441ba27e8d844710eedbTest

المؤلفون: Reggidori, Nicola, Bucci, Laura, Santi, Valentina, Stefanini, Benedetta, Lani, Lorenzo, Rampoldi, Davide, Ghittoni, Giorgia, Farinati, Fabio, Masotto, Alberto, Stefanini, Bernardo, Mega, Andrea, Biasini, Elisabetta, Foschi, Francesco Giuseppe, Svegliati-Baroni, Gianluca, Sangiovanni, Angelo, Campani, Claudia, Raimondo, Giovanni, Vidili, Gianpaolo, Gasbarrini, Antonio, Celsa, Ciro, Di Marco, Mariella, Giannini, Edoardo G., Sacco, Rodolfo, Brunetto, Maurizia Rossana, Azzaroli, Francesco, Magalotti, Donatella, Morisco, Filomena, Rapaccini, Gian Ludovico, Nardone, Gerardo, Vitale, Alessandro, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Benevento, Francesca, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Allegrini, Gloria, Cammà, Calogero, Cabibbo, Giuseppe, Giacchetto, Carmelo Marco, Giuffrida, Paolo, Grassini, Maria Vittoria, Grova, Mauro, Rancatore, Gabriele, Stornello, Caterina, Adotti, Valentina, Cavoli, Tancredi Li

المصدر: JHEP Reports ; volume 5, issue 8, page 100784 ; ISSN 2589-5559

مصطلحات موضوعية: Gastroenterology, Hepatology, Immunology and Allergy, Internal Medicine

الإتاحة: https://doi.org/10.1016/j.jhepr.2023.100784Test
https://api.elsevier.com/content/article/PII:S2589555923001155?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2589555923001155?httpAccept=text/plainTest

المؤلفون: Pollakova, Daniela, Lauria Pantano, Angelo, Di Folco, Ugo, Nardone, Maria Rosaria, Tubili, Claudio

المصدر: Journal of Diabetes Science and Technology ; volume 18, issue 2, page 524-525 ; ISSN 1932-2968 1932-2968

مصطلحات موضوعية: Biomedical Engineering, Bioengineering, Endocrinology, Diabetes and Metabolism, Internal Medicine

الإتاحة: https://doi.org/10.1177/19322968231223254Test

المؤلفون: Pablo Rojo, Cinta Moraleda, Alfredo Tagarro, Sara Domínguez‐Rodríguez, Lola Madrid Castillo, Luis Manuel Prieto Tato, Aránzazu Sancho López, Lilit Manukyan, Olivier Marcy, Valériane Leroy, Alessandra Nardone, David M. Burger, Quique Bassat, Matthew Bates, Raoul Moh, Pui-Ying Iroh Tam, Tisungane Mvalo, Justina Magallhaes, W Chris Buck, Jahit Sacarlal, Victor Musiime, Chishala Chabala, Hilda Mujuru

مصطلحات موضوعية: Epidemiology and Pathogenesis of Pneumocystis Pneumonia, Epidemiology, Medicine, Health Sciences, Epidemiology and Management of Cytomegalovirus Infection, Tuberculosis, Infectious Diseases, FOS Health sciences, HIV, Valganciclovir, Pneumonia, Adverse effect, Clinical endpoint, Randomized controlled trial, Cytomegalovirus, Pediatrics, Internal medicine, Immunology, FOS Clinical medicine, Human cytomegalovirus, Ganciclovir, Human immunodeficiency virus HIV, Viral disease, Virus, Herpesviridae, Pathology

الوصف: Pneumonia is the primary cause of death among HIV-infected children in Africa, with mortality rates as high as 35-40% in infants hospitalized with severe pneumonia. Bacterial pathogens and Pneumocystis jirovecii are well known causes of pneumonia-related death, but other important causes such as cytomegalovirus (CMV) and tuberculosis (TB) remain under-recognized and undertreated. The immune response elicited by CMV may be associated with the risk of developing TB and TB disease progression, and CMV may accelerate disease caused both by HIV and TB. Minimally invasive autopsies confirm that CMV and TB are unrecognized causes of death in children with HIV. CMV and TB may also co-infect the same child. The aim of this study is to compare the impact on 15-day and 1-year mortality of empirical treatment against TB and CMV plus standard of care (SoC) versus SoC in HIV-infected infants with severe pneumonia.This is a Phase II-III, open-label randomized factorial (2 × 2) clinical trial, conducted in six African ... : الالتهاب الرئوي هو السبب الرئيسي للوفاة بين الأطفال المصابين بفيروس نقص المناعة البشرية في أفريقيا، حيث تصل معدلات الوفيات إلى 35-40 ٪ بين الرضع الذين يدخلون المستشفى بالالتهاب الرئوي الحاد. تعد مسببات الأمراض البكتيرية والمكورات الرئوية الجيروفية من الأسباب المعروفة للوفاة المرتبطة بالالتهاب الرئوي، ولكن لا تزال الأسباب المهمة الأخرى مثل الفيروس المضخم للخلايا والسل غير معترف بها ولا يتم علاجها. قد ترتبط الاستجابة المناعية التي أثارها فيروس CMV بخطر تطور مرض السل والسل، وقد يؤدي فيروس CMV إلى تسريع المرض الناجم عن كل من فيروس نقص المناعة البشرية والسل. تؤكد عمليات تشريح الجثث طفيفة التوغل أن الفيروس المضخم للخلايا والسل هي أسباب غير معروفة للوفاة لدى الأطفال المصابين بفيروس نقص المناعة البشرية. قد يصيب فيروس الورم الحليمي البشري والسل نفس الطفل. الهدف من هذه الدراسة هو مقارنة التأثير على وفيات 15 يومًا وسنة واحدة من العلاج التجريبي ضد السل وفيروس CMV بالإضافة إلى معيار الرعاية (SoC) مقابل SoC في الرضع المصابين بفيروس نقص المناعة البشرية المصابين بالالتهاب الرئوي الحاد. هذه هي المرحلة الثانية والثالثة، تجربة ...

العلاقة: https://dx.doi.org/10.60692/1z2rb-k8568Test

الإتاحة: https://doi.org/10.60692/7fhy7-m6r3710.60692/1z2rb-k8568Test

المؤلفون: Di Folco, Ugo, Vallecorsa, Noemi, Nardone, Maria Rosaria, Pantano, Angelo Lauria, Tubili, Claudio

المصدر: Acta Diabetologica ; volume 59, issue 10, page 1287-1294 ; ISSN 1432-5233

مصطلحات موضوعية: Endocrinology, General Medicine, Endocrinology, Diabetes and Metabolism, Internal Medicine

الوصف: Aims Aim of the present study was to evaluate the impact of once-weekly semaglutide on different end-points indicative of metabolic control, cardiovascular risk, dietary behavior, and treatment satisfaction in T2DM. Methods This was a retrospective observational study conducted in a diabetes clinic. Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed. Furthermore, at T1 patients were asked to fill-in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Control of Eating Questionnaire (COEQ). Results Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years). After 32 weeks of treatment with semaglutide, HbA1c levels were reduced by 1.38%, FBG by − 56.53 mg/dl, weight by 6.03 kg. Systolic and diastolic blood pressure, total, HDL-, LDL-, and non –HDL cholesterol, and triglycerides significantly improved. The number of glucose-lowering and antihypertensive drugs also decreased. At T1, DTSQ score was 32.23 ± 1.44, whereas COEQ indicated low levels of hunger and good control of eating. Conclusions The study documented benefits of semaglutide on metabolic control and multiple CV risk factors, simplification of therapeutic schemes and high satisfaction with diabetes treatment, and eating behaviors indicative of healthy diet and reduced food intake.

الإتاحة: https://doi.org/10.1007/s00592-022-01936-6Test

المؤلفون: Ugo Di Folco, Noemi Vallecorsa, Maria Rosaria Nardone, Angelo Lauria Pantano, Claudio Tubili

المصدر: Acta Diabetologica. 59:1287-1294

مصطلحات موضوعية: Glycated Hemoglobin, Male, Endocrinology, Diabetes and Metabolism, Glucagon-Like Peptides, Feeding Behavior, General Medicine, Middle Aged, Endocrinology, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Heart Disease Risk Factors, Risk Factors, Internal Medicine, Humans, Hypoglycemic Agents, Female, Antihypertensive Agents, Aged

الوصف: Aims Aim of the present study was to evaluate the impact of once-weekly semaglutide on different end-points indicative of metabolic control, cardiovascular risk, dietary behavior, and treatment satisfaction in T2DM. Methods This was a retrospective observational study conducted in a diabetes clinic. Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed. Furthermore, at T1 patients were asked to fill-in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Control of Eating Questionnaire (COEQ). Results Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years). After 32 weeks of treatment with semaglutide, HbA1c levels were reduced by 1.38%, FBG by − 56.53 mg/dl, weight by 6.03 kg. Systolic and diastolic blood pressure, total, HDL-, LDL-, and non –HDL cholesterol, and triglycerides significantly improved. The number of glucose-lowering and antihypertensive drugs also decreased. At T1, DTSQ score was 32.23 ± 1.44, whereas COEQ indicated low levels of hunger and good control of eating. Conclusions The study documented benefits of semaglutide on metabolic control and multiple CV risk factors, simplification of therapeutic schemes and high satisfaction with diabetes treatment, and eating behaviors indicative of healthy diet and reduced food intake.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05a134ff082b9a601ead18a2dbe54254Test
https://doi.org/10.1007/s00592-022-01936-6Test

المؤلفون: Jaehyuk Choi, Beatrice Nardone, Abu Jaafar Zaidi, Walter Liszewski

المصدر: Journal of the American Academy of Dermatology. 86:1120-1123

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Skin Neoplasms, Merkel cell carcinoma, business.industry, Dermatology, medicine.disease, Carcinoma, Merkel Cell, Internal medicine, medicine, Humans, Skin cancer, Presentation (obstetrics), business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee0aff171258879087c65a9ebebe2d7Test
https://doi.org/10.1016/j.jaad.2021.04.019Test

المؤلفون: Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, Romagnoli, Veronica

المساهمون: Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, Romagnoli, Veronica

المصدر: Liver Cancer International. 2:45-53

مصطلحات موضوعية: Liver Cancer, Pre-TACE-Predict model, medicine.medical_specialty, business.industry, Trans-arterial chemoembolization, Pharmaceutical Science, hepatocellular carcinoma, medicine.disease, Gastroenterology, Complementary and alternative medicine, Internal medicine, Hepatocellular carcinoma, medicine, Pharmacology (medical), Trans arterial chemoembolization, business

الوصف: Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treated with trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role. Methods We performed an independent external validation of the Pre-TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008-2018) were used to assess calibration and discrimination of the Pre-TACE-Predict model. Results The four risk-categories identified by the Pre-TACE-Predict model had gradient monotonicity, with median survivals of 52.0, 36.2, 29.9, and 14.1 months respectively. However, predicted survivals systematically underestimated observed survivals (R2: 0.667). A recalibration was adopted maintaining fixed the prognostic index and modifying the baseline survival function. This resulted in an almost perfect calibration (R2: 0.995) in all the four risk categories. Cox regressions showed that aetiology and macrovascular invasion, included in the Pre-TACE-Predict model, had no prognostic impact in the present study population, and that coefficients for tumour size and multiplicity were overestimated. The c-index was similar to that of the m-HAP-III, but higher than those of HAP, m-HAP-II and the six-and-twelve models. Conclusions The recalibration of Pre-TACE-Predict model improved the estimation of survival probabilities of HCC patients treated with TACE. The highest discriminatory ability of the Pre-TACE-model in comparison to other available models, together with risk stratification and recalibration, makes it the best prognostic tool currently available for these patients.

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbde9317073d2681c6ff57d21dc136a8Test
https://doi.org/10.1002/lci2.33Test

المؤلفون: Filippo Pelizzaro, Giulia Peserico, Marco D'Elia, Nora Cazzagon, Francesco Paolo Russo, Alessandro Vitale, Edoardo G. Giannini, Manuela Piccinnu, Gian Ludovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Marco Zoli, Rodolfo Sacco, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Filomena Morisco, Antonio Gasbarrini, Gianluca Svegliati-Baroni, Francesco Giuseppe Foschi, Andrea Olivani, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Franco Trevisani, Fabio Farinati, Maurizio Biselli, Paolo Caraceni, Francesca Garuti, Annagiulia Gramenzi, Andrea Neri, Valentina Santi, Fabio Piscaglia, Francesco Tovoli, Alessandro Granito, Luca Muratori, Francesca Benevento, Elton Dajti, Giovanni Marasco, Federico Ravaioli, Alberta Cappelli, Rita Golfieri, Cristina Mosconi, Matteo Renzulli, Angela Imondi, Anna Sartori, Barbara Penzo, Elisa Pinto, Ester Marina Cela, Antonio Facciorusso, Valentina Cacciato, Edoardo Casagrande, Alessandro Moscatelli, Gaia Pellegatta, Nicoletta De Matthaeis, Gloria Allegrini, Valentina Lauria, Giorgia Ghittoni, Giorgio Pelecca, Fabrizio Chegai, Fabio Coratella, Mariano Ortenzi, Gabriele Missale, Alessandro Inno, Fabiana Marchetti, Anita Busacca, Calogero Cammà, Vincenzo Di Martino, Giacomo Emanuele Maria Rizzo, Maria Stella Franzè, Carlo Saitta, Assunta Sauchella, Vittoria Bevilacqua, Alberto Borghi, Andrea Casadei Gardini, Fabio Conti, Anna Chiara Dall'aglio, Giorgio Ercolani, Federica Mirici, Claudia Campani, Chiara Di Bonaventura, Stefano Gitto, Pietro Coccoli, Antonio Malerba, Maria Guarino, Maurizia Brunetto, Veronica Romagnoli

المساهمون: Pelizzaro, F., Peserico, G., D'Elia, M., Cazzagon, N., Russo, F. P., Vitale, A., Giannini, E. G., Piccinnu, M., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, A., Svegliati-Baroni, G., Foschi, F. G., Olivani, A., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Farinati, F., Biselli, M., Caraceni, P., Garuti, F., Gramenzi, A., Neri, A., Santi, V., Piscaglia, F., Tovoli, F., Granito, A., Muratori, L., Benevento, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Imondi, A., Sartori, A., Penzo, B., Pinto, E., Cela, E. M., Facciorusso, A., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., De Matthaeis, N., Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Missale, G., Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Borghi, A., Casadei Gardini, A., Conti, F., Dall'Aglio, A. C., Ercolani, G., Mirici, F., Campani, C., Di Bonaventura, C., Gitto, S., Coccoli, P., Malerba, A., Guarino, M., Brunetto, M., Romagnoli, V., Pelizzaro, Filippo, Peserico, Giulia, D'Elia, Marco, Cazzagon, Nora, Russo, Francesco Paolo, Vitale, Alessandro, Giannini, Edoardo G., Piccinnu, Manuela, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Trevisani, Franco, Farinati, Fabio, Biselli, Maurizio, Caraceni, Paolo, Garuti, Francesca, Gramenzi, Annagiulia, Neri, Andrea, Santi, Valentina, Piscaglia, Fabio, Tovoli, Francesco, Granito, Alessandro, Muratori, Luca, Benevento, Francesca, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Imondi, Angela, Sartori, Anna, Penzo, Barbara, Pinto, Elisa, Cela, Ester Marina, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, Moscatelli, Alessandro, Pellegatta, Gaia, De Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Missale, Gabriele, Inno, Alessandro, Marchetti, Fabiana, Busacca, Anita, Cammà, Calogero, Di Martino, Vincenzo, Rizzo, Giacomo Emanuele Maria, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Bevilacqua, Vittoria, Borghi, Alberto, Casadei Gardini, Andrea, Conti, Fabio, Dall'aglio, Anna Chiara, Ercolani, Giorgio, Mirici, Federica, Campani, Claudia, Di Bonaventura, Chiara, Gitto, Stefano, Coccoli, Pietro, Malerba, Antonio, Guarino, Maria, Brunetto, Maurizia, Romagnoli, Veronica

مصطلحات موضوعية: medicine.medical_specialty, Carcinoma, Hepatocellular, Survival, Hepatocellular carcinoma, Cancer stage, Surveillance interval, Internal medicine, medicine, Humans, Propensity Score, Survival analysis, High risk patients, Hepatology, business.industry, Liver Neoplasms, Settore MED/09 - MEDICINA INTERNA, Gastroenterology, Patient survival, medicine.disease, Survival Analysis, Propensity score matching, Survival Analysi, Liver cancer, business, Median survival, Human

الوصف: Background An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC). Aims We compared the 3- and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival. Methods Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching. Results The 3-months surveillance interval neither reduced the share of patients diagnosed outside the Milano criteria, nor increased their probability to receive curative treatments. The median survival of 6MS patients (55.0 months [45.9–64.0]) was not significantly different from the observed (47.0 months [35.0–58.9]; p = 0.43) and adjusted (44.9 months [33.4–56.4]; p = 0.30) survival of 3MS patients. A propensity score analysis confirmed the absence of a survival advantage for 3MS patients. Conclusions A tightening of surveillance schedule does not increase the diagnosis of early-stage tumors, the feasibility of curative treatments and the survival. Therefore, we should maintain the 6-months interval in the surveillance of viral cirrhotics.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01102de056de39cda9bb991a53e21a77Test
https://hdl.handle.net/11577/3409825Test

المؤلفون: Carmelo Scarpignato, Adi Lahat, Giovanni Barbara, Angel Lanas, Valerio Papa, Tomica Milosavljeviĉ, Giovanni Brandimarte, Antonio Tursi, Gerardo Nardone, Neil Stollman

المساهمون: Milasavljevic, T., Brandimarte, G., Stollman, N., Barbara, G., Lahat, A., Scarpignato, C., Lanas, A., Papa, V., Tursi, A., Nardone, G., Milasavljevic T., Brandimarte G., Stollman N., Barbara G., Lahat A., Scarpignato C., Lanas A., Papa V., Tursi A., Nardone G.

المصدر: Journal of Gastrointestinal and Liver Diseases. 28:11-16

مصطلحات موضوعية: medicine.medical_specialty, Diverticular Disease, Settore MED/18 - CHIRURGIA GENERALE, Colonoscopy, Segmental colitis associated with diverticulosi, Disease, Diagnosis, Differential, Irritable Bowel Syndrome, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Mesalazine, Risk Factors, Internal medicine, Diagnosis, Secondary Prevention, medicine, Humans, Diverticulitis, Diverticuliti, Irritable bowel syndrome, Diverticular Diseases, medicine.diagnostic_test, business.industry, Risk Factor, Gastroenterology, food and beverages, medicine.disease, Colorectal cancer, 3. Good health, Rifaximin, Diverticulosis, chemistry, 030220 oncology & carcinogenesis, Differential, Acute Disease, Disease Progression, Diverticular disease, 030211 gastroenterology & hepatology, Segmental colitis associated with diverticulosis, business, Human

الوصف: In this session several critical issues in diverticular disease were considered, including “It is Symptomatic Diverticular Disease or Irritable Bowel Syndrome?”, “What do determine evolution to diverticulitis, bowel habits alteration or inflammation?”, and “Prevention of acute diverticulitis: Is it at all possible?”. The first talking compared symptoms and laboratory findings between Symptomatic Uncomplicated Diverticular Disease (SUDD) and Irritable Bowel Syndrome (IBS). Although both disease share some symptoms, and although IBS can occur in patients having diverticulosis, SUDD and IBS can be differentiate using a combination of symptoms and laboratory tools. The second talking debated what are the most important risk factors for the evolution towards acute diverticulitis. Current data seem to exclude a significant role of bowel habits alteration, while inflammation seems to have a stronger role, especially in causing acute diverticulitis recurrence. The third talking analyzed about the acute diverticulitis prevention. Primary prevention seem to be little better when using mesalazine, while no definite conclusion can be drawn about the use of fiber and rifaximin. About the secondary prevention, no drugs can be currently advised due to lacking of definite results. At the same time, surgery should be advised on case-by-case basis.

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3184193d94b98b3ccf452972be1cef3Test
https://doi.org/10.15403/jgld-552Test